| Literature DB >> 33850820 |
Lanqiong Zhou1, Xu Song1, Hongzhu Lu1, Yajun Mao1, Chengbo Liu2, Yan Yuan3, Qihong Fan1.
Abstract
BACKGROUND: The novel coronavirus disease 2019 (COVID-19) epidemic has spread globally, along with its incidence among children. The purpose of this study was to evaluate the clinical characteristics and outcomes of children infected with COVID-19 and to provide a reference for clinical work.Entities:
Keywords: Coronavirus disease 2019 (COVID-19); children; clinical features; outcome
Year: 2021 PMID: 33850820 PMCID: PMC8039793 DOI: 10.21037/tp-21-48
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
General clinical features of children with COVID-19
| Case | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| Clinical type | Mild | Mild | Mild | Mild | Moderate | Asymptomatic | Mild |
| Gender | Female | Female | Male | Female | Female | Male | Female |
| Age | 0.3 | 3 | 9 | 5 | 3 | 12 | 2 |
| Wuhan resident or contact with Wuhan returnees | Y | Y | Y | Y | Y | Y | Y |
| Familial aggregation infection | Y | Y | Y | Y | Y | Y | Y |
| Chest CT | N | N | N | N | Pneumonia | N | N |
| Clinical features Fever | Y | Y | Y | Y | Y | ||
| Cough | Y | Y | Y | Y | Y | ||
| Diarrhea | Y | ||||||
| Eczema | Y | ||||||
| Throat ache | Y | ||||||
| Rhinorrhea | Y | ||||||
| Highest Temp. (°C) | 38.5 | 38.5 | 37.5 | 39.8 | 38.5 |
COVID-19, coronavirus disease 2019; N, normal; Y, yes; CT, computed tomography.
Novel coronavirus infection in children: laboratory results analysis parameter
| Parameter | Number (%) |
|---|---|
| White blood cells (×109/L) | |
| <5.0 | 1 [14] |
| 5.0–12.0 | 5 [71] |
| >12.0 | 1 [14] |
| Neutrophils (×109/L) | |
| <1.8 | 0 |
| 1.8–6.3 | 6 [86] |
| >6.3 | 1 [14] |
| Lymphocytes (×109/L) | |
| <1.1 | 1 [14] |
| 1.1–3.2 | 3 [43] |
| >3.2 | 3 [43] |
| ALT/AST (U/L) | |
| ≤40 | 6 [86] |
| >40 | 1 [14] |
| Lactate dehydrogenase (U/L) | |
| <100 | 0 |
| 100–240 | 4 [57] |
| >240 | 3 [43] |
| CK-MB (U/L) | |
| ≤25 | 5 [71] |
| >25 | 2 [29] |
| C-reactive protein (mg/L) | |
| ≤8 | 5 [71] |
| >8 | 2 [29] |
| Infection with other pathogens | |
| Mycoplasma pneumoniae infection | 1 [14] |
| Mycoplasma pneumoniae with influenza B virus | 3 [43] |
ALT, aspartate aminotransferase; AST, alanine transaminase; CK-MB, creatine kinase-MB.
Figure 1The chest CT images depict typical radiographic findings of COVID-19 pneumonia in Case 5, 3-year-old female, 4 February 2020. (A) The upper lobe of the left lung shows infectious lesions with ground glass shadow. (B) The dorsal segment of the lower lobe shows infectious lesions with ground glass shadow. CT, computed tomography; COVID-19, coronavirus disease 2019. The “arrows” mark the location of infectious lesions.
Figure 2The image depicts the change of chest CT images in Case 5 from 8 February 2020 to 28 February 2020. (A) Compared to 4 February 2020, the lung CT on 8 February 2020 shows the lesions in the left upper lobe are smaller than those in the front, with lower density, consolidation of some lesions in the front of the upper lobe, new fibrous lesions in the lingula, and basic absorption of infectious lesions in the posterior lower lobe of the left lung compared with those in the anterior, taking into account the change of the transformation period of the lesions; (B) compared to 8 February 2020, the lung CT on 12 February 2020 shows the lesions in the left upper lobe of the lung decreased in size and density, the consolidation lesions in the anterior segment of the upper lobe decreased, and the absorption of the fibrosis lesions in the lingula disappeared; (C) compared to 12 February 2020 CT, the lung CT on 28 February 2020 shows the lesions were basically absorbed, and there was no obvious abnormality in lung CT plain scan. CT, computed tomography. The “arrows” mark the location of infectious lesions.
The treatment and outcome of COVID-19 infection in children.
| Clinical data (Case no.) | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| Clinical typing | Mild | Mild | Mild | Mild | Moderate | Asymptomatic | Mild |
| Ending | RD | RD | RD | RD | RD | RD e | RD |
| Duration of positive nucleic acid test (two consecutive intervals of 24 hours) (days) | 26 | 11 | 15 | 14 | 13 | 6 | 14 |
| Length of stay (days) | 31 | 12 | 16 | 15 | 12 | 8 | 17 |
| Treatment | |||||||
| Interferon atomization | Y | Y | Y | Y | Y | Y | Y |
| Lianhua Qingwen | Y | Y | Y | Y | Y | Y | |
| Inosine | Y | ||||||
| Reduced glutathione | Y | ||||||
| Abidol | Y | Y | Y | Y | Y | ||
| Oseltamivir | Y | Y | Y | ||||
| Azithromycin | Y | Y | Y | Y | |||
| TCM | Y | Y | Y | Y | |||
| Leucogen | Y |
COVID-19, coronavirus disease 2019; RD, recovery and discharge; TCM, Traditional Chinese medicine; Y, yes.